Elizabeth Yeu Lin, Chief Medical Officer at Tarsus Pharmaceuticals, sold TARS on Sep 4, 2026
Data as of Oct 16
▼ SELL$458K5,387 shares at $85.00Elizabeth Yeu Lin Chief Medical OfficerTARS Tarsus Pharmaceuticals, Inc.
- Traded
- Sep 4, 2026
- Disclosed
- Sep 9, 2026
- Filed
- 5 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
TARS since disclosure
−17.8%
after the sale
Similar stocks (XLV) since disclosure
+6.1%
XLV — its sector index fund
Change in closing price from Sep 9, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLElizabeth Yeu Lin Chief Medical OfficerTARS Tarsus Pharmaceuticals, Inc.$485Kdisclosed Sep 9 · filed 5 days after the trade · late
- ▼ SELLElizabeth Yeu Lin Chief Medical OfficerTARS Tarsus Pharmaceuticals, Inc.$143Kdisclosed Sep 9 · filed 5 days after the trade · late
- ▼ SELLElizabeth Yeu Lin Chief Medical OfficerTARS Tarsus Pharmaceuticals, Inc.$135Kdisclosed Sep 9 · filed 5 days after the trade · late